Recent News

• 09.11.2025 - Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225
• 09.09.2025 - Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit
• 09.05.2025 - Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September
• 09.03.2025 - Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research
• 08.27.2025 - Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
• 08.14.2025 - Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
• 08.07.2025 - Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025
• 07.02.2025 - Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option

Recent Filings

• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.14.2025 - 8-K Current report
• 08.14.2025 - EX-99.1 EX-99.1
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.08.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 07.08.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 07.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.03.2025 - 4 Statement of changes in beneficial ownership of securities